Crystal Diagnostics CDx is a company that is dedicated to improving the safety of food through innovative technology solutions. Established in 2003 as a result of a research partnership with Kent State University and Northeast Ohio Medical University (NEOMED), the company has made significant strides in the field of food pathogen detection. With a focus on biotechnology and healthcare, Crystal Diagnostics has developed the AutoXpress, a cutting-edge platform for food safety testing that surpasses existing systems in the market.
Crystal Diagnostics sets itself apart with its commitment to providing a low-cost, fully automated, and highly accurate platform that is conducive to high throughput environments. Additionally, the company's solutions offer cost-saving benefits and improve laboratory practices. With a robust R&D team and 19 patents under its belt, Crystal Diagnostics has proven its dedication to advancing automation through the use of liquid crystal technology.
Despite encountering challenges due to the lack of specific information about the headquarter and the last investment round, it's notable that the company received a $905.00K Convertible Note investment on 13th July 2013. This represents a vote of confidence from investors in the company's potential.
Crystal Diagnostics CDx stands at the forefront of revolutionizing food safety and is well-positioned to make a significant impact on the industry. With its fully integrated in-house manufacturing, R&D, and engineering teams, the company is dedicated to delivering the highest quality products to the market.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Convertible Note | $905.00K | - | 13 Jul 2013 | |
Venture Round | $1.00M | - | 12 Jan 2012 |
No recent news or press coverage available for Crystal Diagnostics CDx.